OTCMKTS:DGNOF DIAGNOS (DGNOF) Stock Price, News & Analysis → Trump’s Gift Could Unleash $51 Billion in New Wealth (From Wealthpin Pro) (Ad) Free DGNOF Stock Alerts $0.23 +0.01 (+4.62%) (As of 06/11/2024 ET) Add Compare Share Share Today's Range$0.23▼$0.2350-Day Range$0.19▼$0.2552-Week Range$0.18▼$0.43Volume20,000 shsAverage Volume31,370 shsMarket Capitalization$17.39 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsHeadlinesShort InterestStock AnalysisChartEarningsHeadlinesShort Interest Get DIAGNOS alerts: Email Address Ad StockEarningsYour Special Report - Top 7 Summer StocksSummer is almost Here! I would like to give you a special report that could help boost your portfolio this summer (and beyond). It’s called 7 Best Stocks to Own in Summer 2024.Get Your Copy of "7 Best Stocks to Own in Summer 2024" Here. About DIAGNOS Stock (OTCMKTS:DGNOF)DIAGNOS Inc. provides software-based services primarily in Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. The company offers healthcare services through Computer Assisted Retina Analysis, a web-based software tool that assists healthcare professionals for the detection of diabetic retinopathy; and allows eye care specialist to visualize both normal retinal landmarks and pathological changes. It also provides various consulting services in the fields of data analysis and artificial intelligence. DIAGNOS Inc. was founded in 1998 and is headquartered in Brossard, Canada.Read More DGNOF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DGNOF Stock News HeadlinesJune 5, 2024 | globenewswire.comDIAGNOS Announces Closing of Second and Final Tranche of Private PlacementMay 21, 2024 | globenewswire.comDIAGNOS celebrates the launch of Labtician's new screening service for diabetic retinopathy in Ontario and renews its distribution agreementMay 9, 2024 | globenewswire.comDIAGNOS Announces Closing of First Tranche of Private PlacementMay 6, 2024 | globenewswire.comDIAGNOS to Present Cutting-Edge AI Solutions for Retinal Health at ARVO 2024April 16, 2024 | globenewswire.comDIAGNOS to expedite application for Medical Device License to Health Canada and US FDA related to its 4 new analysis modules, and is planning ISO 27001 certificationApril 9, 2024 | globenewswire.comDIAGNOS Inc. to Present at the AI & Technology Hybrid Investor Conference April 11thApril 3, 2024 | globenewswire.comDIAGNOS Announces Grant of Stock OptionsApril 2, 2024 | globenewswire.comDIAGNOS Welcomes Dr. Philippe Couillard to its Board of DirectorsMarch 22, 2024 | globenewswire.comDIAGNOS Announces Closing of Second and Final Tranche of Private PlacementMarch 4, 2024 | globenewswire.comDIAGNOS Announces Grant of Stock OptionsFebruary 29, 2024 | globenewswire.comDIAGNOS Welcomes Mr. Michael Braeuel to its Board of DirectorsFebruary 27, 2024 | globenewswire.comDIAGNOS Announces Closing of First Tranche of Private PlacementFebruary 23, 2024 | globenewswire.comDiagnos Announces Variation in One Insider Ownership of Common SharesFebruary 21, 2024 | globenewswire.comDIAGNOS recognized as a Top TSX Venture Exchange CompanyDecember 8, 2023 | nytimes.comBest of 2023See More Headlines Receive DGNOF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DIAGNOS and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today6/11/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorBusiness Services Industry Private households Sub-IndustryN/A Current SymbolOTCMKTS:DGNOF CUSIPN/A CIKN/A Webwww.diagnos.ca Phone(450) 678-8882FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,880,000.00 Net Margins-1,553.79% Pretax Margin-1,032.49% Return on EquityN/A Return on Assets-297.10% Debt Debt-to-Equity RatioN/A Current Ratio0.79 Quick Ratio0.79 Sales & Book Value Annual Sales$370,000.00 Price / Sales47.01 Cash FlowN/A Price / Cash FlowN/A Book Value($0.02) per share Price / Book-11.33Miscellaneous Outstanding Shares76,770,000Free FloatN/AMarket Cap$17.39 million OptionableNot Optionable Beta0.19 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Andre LarenteCEO, President & Executive ChairmanMr. Marc-André MassueVP of Finance, CFO & SecretaryMr. Yves-Stéphane CoutureChief Operating OfficerMr. Martin BelandDirector of MarketingKey CompetitorsWentworth ResourceOTCMKTS:WENTFCirataOTCMKTS:WANSFTotal BrainOTCMKTS:BRRZYVoyager DigitalOTCMKTS:VYGVFWolford AktiengesellschaftOTCMKTS:WLFDYView All Competitors DGNOF Stock Analysis - Frequently Asked Questions How have DGNOF shares performed in 2024? DIAGNOS's stock was trading at $0.3050 at the start of the year. Since then, DGNOF stock has decreased by 25.7% and is now trading at $0.2266. View the best growth stocks for 2024 here. How do I buy shares of DIAGNOS? Shares of DGNOF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:DGNOF) was last updated on 6/12/2024 by MarketBeat.com Staff From Our PartnersYour Special Report - Top 7 Summer StocksSummer is almost Here! I would like to give you a special report that could help boost your portfolio this sum...StockEarnings | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredThe Hidden Tax Advantages of America’s #1 Inheritance StockWall Street Millionaire: BUY "America's #1 Legacy Stock" The man CNBC called "The Prophet" bought AAPL at $...Stansberry Research | SponsoredBill Clinton Backing Biden Replacement???Louis Navellier — a frequent guest at Mar-a-Lago — ruffled many in his own circles when he declared over a yea...The Freeport Society | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DIAGNOS Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DIAGNOS With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.